Camus G, et al. - Researchers sought to delineate the resistance profile of ledipasvir (LDV) and velpatasvir (VEL) in patients with genotype 4 (GT4) hepatitis C virus (HCV) infection. Here, irrespective of the subtype or presence of resistance-associated substitutions (RASs), all patients achieved SVR12 in GS-US-342-1138. In vitro data supported that VEL was potent against all GT4 isolates tested.